ライフサイエンスコーパス: T-cell response

1 ent points of intervention for modifying the T cell response.

2 althy blood donors with a predominantly CD4+ T cell response.

3 Cs) that mediated immune escape by impairing T cell response.

4 of aggregates on DCs and consequently on the T cell response.

5 gens and challenging mice at the peak of the T cell response.

6 tibility complex (MHC) class I-primed CD8(+) T cell response.

7 le for the induction of a virus-specific CD8 T cell response.

8 physical restoration of the antigen-specific T cell response.

9 f antigen-specific models to interrogate the T cell response.

10 sponds to immunosuppression of an Ag-induced T cell response.

11 ng of the antigenic landscape of the overall T cell response.

12 ificantly higher EBOV-specific CD8+ and CD4+ T-cell response.

13 and subsequent hyperactivation of the CD8(+) T-cell response.

14 turation and subsequently reduced allogeneic T-cell response.

15 ing orientations and the ability to induce a T-cell response.

16 nate immune responses and adaptive cytotoxic T cell responses.

17 elayed kinetics and induce suboptimal CD8(+) T cell responses.

18 inducing potent cytotoxic CD4(+) and CD8(+) T cell responses.

19 key determinant of Ag specificity in CD8(+) T cell responses.

20 ponsive macrophage population, and activated T cell responses.

21 ith induction of neutralizing antibodies and T cell responses.

22 enerating potent tumor antigen-specific CD8+ T cell responses.

23 to human T helper type 1 (Th1) and cytotoxic T cell responses.

24 ostimulatory molecules that promote improved T cell responses.

25 rm targeting CD169(+) DCs to drive antitumor T cell responses.

26 opes in vaccine cells which activate de novo T cell responses.

27 e frequency of Ebola GP-specific CD4 and CD8 T cell responses.

28 of circulating Tregs and reduced anti-donor T cell responses.

29 eveal the mechanisms by which PD-1 regulates T cell responses.

30 al inhibitory receptor that limits excessive T cell responses.

31 dritic cells can enhance induction of Ab and T cell responses.

32 l features involved in the generation of CD8 T cell responses.

33 y promoting rather than terminating effector T cell responses.

34 ) T cell responses predominating over CD8(+) T cell responses.

35 igs combined high Ab titers and strong local T cell responses.

36 oles in both naive T cell priming and memory T cell responses.

37 enabled us to closely monitor and quantitate T cell responses.

38 icrobiome shifts and enhanced intestinal CD8 T cell responses.

39 elicit broadly protective CD4(+) and CD8(+) T cell responses.

40 n is associated with enhanced HIV-1-specific T cell responses.

41 cells and the induction of protective CD8(+) T cell responses.

42 can be attributed to defective Th1 and CD8+ T cell responses.

43 cination approach to activate tumor-specific T cell responses.

44 lope V2 loop and of envelope-specific CD4(+) T cell responses.

45 in the elicitation of antibody and cytotoxic T cell responses.

46 Ankara vector to induce HBV-specific B- and T-cell responses.

47 responses and low or undetectable Th2 or CD8 T-cell responses.

48 characterized by poor LASV-specific effector T-cell responses.

49 ster of differentiation 8-positive (CD8(+) ) T-cell responses.

50 cytokine staining to measure HIV-1-specific T-cell responses.

51 virus and poor Lassa virus-specific effector T-cell responses.

52 C, therefore, induce qualitatively different T-cell responses.

53 ciated with a significant increase in CD4(+) T-cell responses.

54 on of innate immune factors, antibodies, and T-cell responses.

55 broad induction of FSP-specific CD8 and CD4 T-cell responses.

56 mucosal and systemic antibodies and systemic T-cell responses.

57 we demonstrate that contraction of lung CD8+ T cell responses after influenza infection is contempori

58 , we observed a dominant polyfunctional CD8+ T-cell response after natural mumps virus (MuV) infectio

59 infected study participants in terms of CD4+ T-cell responses after anti-CD3 stimulation (P = .19) al

60 in-Barr virus and influenza virus can elicit T cell responses against abnormally expressed cellular a

61 ied role of these PARPs in the modulation of T cell responses against AT-3-induced breast tumors.

62 ions can generate neoantigens that drive CD8 T cell responses against cancer.

63 iming and effector phases, provokes systemic T cell responses against dominant and subdominant neoant

64 Effective T cell responses against infections and tumors require a

65 e parasites can induce protective memory CD8 T cell responses against liver-stage malaria; however, w

66 munospot (ELISPOT) assay to characterize the T cell responses against peptide pools derived from the

67 cine was safe and elicited mutation-specific T cell responses against predicted neoepitopes not detec

68 humoral responses, it blunted type 1 CD4(+) T cell responses against the SIV envelope protein and fa

69 Moreover, robust T-cell responses against 5 selected MuV epitopes could b

70 We demonstrated recipient anti-CAR T-cell responses against a murine single-chain variable

71 ing noninfectious SIV particles and inducing T-cell responses against all nine SIV proteins.

72 ofunctional and polyfunctional CD4+ and CD8+ T-cell responses against influenza A/H1N1, A/H3N2, and B

73 d to clear bacteria and to regulate adaptive T-cell responses against microbes.

74 than facilitates, effector and memory CD4(+) T-cell responses against Salmonella in mice.

75 strate that cross-reactivity at the level of T cell responses among different flaviviruses is very li

76 Therefore, the magnitude of the antitumor T cell response and the corresponding downstream IFN-gam

77 lation, thus impairing virus-specific CD8(+) T cell response and virus control in vivo.

78 o the longevity of beta cell-specific CD8(+) T cell responses and document the use of this methylatio

79 rsus acute viral infections and identify CD8 T cell responses and downstream anorexia as driver mecha

80 ine vector is not likely to generate optimal T cell responses and might thus impair vaccine performan

81 hemokines involved in generation of effector T cell responses and migration of inflammatory cells to

82 d antigen presentation, enhanced anti-tumour T cell responses and reduced tumour growth in syngeneic

83 depletion also impaired allospecific memory T cell responses and thereby enhanced donor hematopoieti

84 ed that chronic inflammation interferes with T-cell response and macrophage function and is also detr

85 All showed a maintained SARS-CoV-2 T-cell response and poor cross-response to other coronav

86 ur findings indicate that poor LASV-specific T-cell responses and activation of nonspecific T cells w

87 epitopes with the potential for stimulating T-cell responses and B-cell antibodies against LASV and

88 llomavirus (HPV) E6-specific and E7-specific T-cell responses and cervical lesion regression in patie

89 el, Tregs are known to inhibit effector CD8+ T-cell responses and contribute to virus persistence.

90 ubjects exhibiting significantly blunted CD4 T-cell responses and diminished antibody responses.

91 s of tumour cells induced systemic cytotoxic T-cell responses and immunological memory associated wit

92 nduced type 1 helper T-cell (Th1)-biased CD4 T-cell responses and low or undetectable Th2 or CD8 T-ce

93 We further assessed HIV-specific T-cell responses and post-ART viral loads.

94 r, the effects of chronic viral infection on T-cell responses and vaccination against highly pathogen

95 peptides were shown to activate this type of T cell response, and four out of these contain class I a

96 temic and mucosal immunoglobulin A (IgA) and T cell responses, and almost entirely prevents SARS-CoV-

97 ory receptor expression, HBV-specific CD4(+) T cell responses, and augmentation by checkpoint blockad

98 eptor programmed cell death 1 (PD1) inhibits T cell responses, and blockade of this interaction has p

99 echanistically, alphaCD40/ICB primed durable T cell responses, and efficacy required DCs and host exp

100 D614G mutant(2) SARS-CoV-2 as well as CD8(+) T cell responses, and protects against SARS-CoV-2 infect

101 thy young adults that VZV-specific B and CD4 T cell responses are detectable in bone marrow (BM) and

102 When CD8(+) T cell responses are inhibited, HSV-1 can reactivate, an

103 Untoward effector CD4+ T cell responses are kept in check by immune regulatory

104 CD8+ T cell responses are necessary for immune control of sim

105 d factors determining successful mounting of T cell responses are poorly defined.

106 Chen et al. revealed that initial CD4+ T cell responses are similar during early infection and

107 s, suggesting that both cytotoxic and helper T-cell responses are important.

108 ctive and induced SARS-CoV-2-specific CD8(+) T cell responses as potentially important determinants o

109 ines induces strong type 1 CD4(+) and CD8(+) T cell responses, as well as long-lived plasma and memor

110 ion of MHC-II and CD86, and induced a memory T-cell response, attenuating tumor onset and growth afte

111 imited cross-reactivity for both CD4 and CD8 T cell responses between flaviviruses and have implicati

112 sed to measure the frequency of EBV-specific T-cell responses between groups following stimulation wi

113 lations substantially impaired the secondary T cell response, both locally and systemically.

114 ereas Aer induced powerful respiratory tract T cell responses but a low titer of Abs.

115 cination had higher baseline MA-specific CD8 T cell responses but no evidence for improved functional

116 the main targets of the Lassa virus-specific T cell responses, but, to date, only a few T cell epitop

117 agonist (4C12) intensified the magnitude of T cell responses by 27%.

118 Strong, Th1-skewed T cell responses can drive protective humoral and cell-m

119 HLA-restricted T cell responses can induce antitumor effects in cancer

120 nctional capacity of peptide-specific CD4(+) T-cell responses characterized after vaccination, are co

121 rsely associated with H3.3K27M-reactive CD8+ T cell responses.CONCLUSIONAdministration of the H3.3K27

122 we established that epitope-specific CD8(+) T cell responses contribute to parasite killing followin

123 Total and spike-specific T cell responses correlated with spike-specific antibody

124 tralization (microneutralization assay), and T-cell responses (cytokine staining).

125 Tonsillar and systemic T-cell responses differed between influenza strains, and

126 om immunotherapy results from an exaggerated T-cell response directed against normal tissue, resultin

127 or inhibition of bacterial antigen-specific T cell responses does not alter the efficacy of BCG-indu

128 ken together, TBE vaccination induced CD4(+) T cell responses dominated by IL-2 and TNF production to

129 and Coss et al. explored virus-specific CD4+ T cell response during HCV infection.

130 d interventions enhanced SIV-specific CD8(+) T cell responses during ART or viral control after ART i

131 lex class I tetramer, we interrogated CD8(+) T cell responses during CHIKV infection.

132 sting and induced SARS-CoV-2-specific CD8(+) T cell responses during the natural course of SARS-CoV-2

133 e of HLA-B*57:01 on the deterioration of CD8 T-cell responses during HIV infection in the absence of

134 demonstrated that SYIPSAEKI-specific CD8(+) T cell responses elicited by viral-vectored CSP-expressi

135 and generalizable strategy for enhancing the T-cell responses elicited by subunit vaccines.

136 al vaccine therapies that could mount robust T cell responses, enhance tumor killing, and provide cli

137 jacent lung, suggesting a less tumor-focused T cell response, exhibit inferior survival.

138 Influenza-specific CD8+ T-cell responses expanded before the appearance of plasm

139 which HCV infection modulates donor-specific T cell responses following LT and the influence of HCV e

140 n only, implying the importance of cytotoxic T-cell responses for the former and CD4(+) T-cell helper

141 Unexpectedly, HPV-specific T cell responses from OPC patients were not constrained

142 gs with INO-4800 we measure antigen-specific T cell responses, functional antibodies which neutralize

143 Our results illustrate the heterogeneity of T cell responses, furthering our understanding of inflam

144 Early and robust T cell responses have been associated with survival from

145 metabolic pathways that underly normal human T cell responses have taught us that there is still much

146 tudied at the level of B-cell responses, CD4 T-cell responses have not yet been examined.

147 HIV-1-specific CD4 and CD8 T-cell responses have remained absent at 27 months.

148 CD4(+) Th1 responses predominate over CD8(+) T cell responses, have a more inflammatory profile, and

149 vides crucial co-stimulatory signals for CD4 T cell responses, however the precise cellular interacti

150 consequences and resulted in diminished CD8 T cell response in adulthood and impaired control of tum

151 nclude IT CMP-001 induces a robust antitumor T cell response in an anti-Qbeta Ab-dependent manner and

152 een previously demonstrated to induce CD8(+) T cell response in Chagas' disease patients, or bind HLA

153 endogenous hepatitis B virus (HBV)-specific T cell response in CHB patients have demonstrated little

154 l epitopes induced a robust antiviral CD4(+) T cell response in the cornea that was associated with p

155 d proteome-wide profiling of HPV-16-specific T cell responses in a cohort of 66 patients with HPV-ass

156 found three novel peptides that induced CD8 T cell responses in at least two Mamu-A1*001-positive an

157 antially more antigen-responsive CD4 and CD8 T cell responses in blood, spleen, bronchoalveolar lavag

158 PD-1 and PD-L1 act to restrict T cell responses in cancer and contribute to self-tolera

159 ent cross-reactive and induced memory CD8(+) T cell responses in cross-sectionally analyzed individua

160 e study of endogenous antigen-specific naive T cell responses in disease and infection, but has been

161 nalysis further suggests a role for specific T cell responses in hereditary versus idiopathic CP path

162 ches to modulate protective and pathological T cell responses in human diseases.

163 ntification of dominant Lassa virus-specific T cell responses in Lassa fever survivors and vaccinated

164 levels of effective Th1-biased antibody and T cell responses in mice after two immunizations.

165 iruses increased the transgene-specific CD8+ T cell responses in mice.

166 Underlying these divergent T cell responses in pancreas and lung cancer are differe

167 a and discuss strategies to directly augment T cell responses in parallel with myeloid cell- and micr

168 reclinical models and can improve anticancer T cell responses in patients with advanced cancers.

169 are effective in restoring exhausted CD8(+) T cell responses in persistent viral infections or tumor

170 YAP slows T cell responses in systemic viral infections and retard

171 Despite robust T cell responses in the lungs, H5N1 (2:6)-infected mice

172 responses to H5N1 impair subsequent adaptive T cell responses in the lungs.

173 document increased HIV-1 Gag-specific CD8(+) T cell responses in the peripheral blood of all nine stu

174 phenotypic landscape of SARS-CoV-2-specific T cell responses in unexposed individuals, exposed famil

175 pes describe here are expected to elicit CD8 T cell responses in up to 87% of the population and coul

176 clearance does not improve HBV-specific CD8+ T cell responses in vivo and may have important implicat

177 influenza-specific TFH-cell (CXCR5+CD57+CD4+ T cell) responses in children, and to a lesser extent in

178 ture that correlated with enhanced cytotoxic T-cell response in human solid tumors.

179 haracteristics of the peanut-specific CD4(+) T-cell response in peanut-allergic patients that correla

180 We investigated EBOV-specific CD8+ and CD4+ T-cell responses in 37 Sierra Leonean EBOV disease survi

181 e development of both anti-ZIKV antibody and T-cell responses in C57BL/6 mice.

182 ogy and suggest that Yap inhibition improves T-cell responses in cancer.

183 ART significantly reduced HIV-specific T-cell responses in HIV controllers but did not adversel

184 se capped nanofibers trigger stronger CD8(+) T-cell responses in mice than uncapped nanofibers.

185 ens/isoallergens are involved in the diverse T-cell responses in ragweed allergic individuals.

186 on triggers a significant increase in CD4(+) T-cell responses in SOT patients.

187 of specificity and dynamics of RSV-specific T-cell responses in the target organ, allowing the preci

188 etion implicates Yap as a mediator of global T-cell responses in the tumor microenvironment and as a

189 for the optimal induction of de novo CD8(+) T-cell responses, in contrast to adjuvants that operate

190 M1 (MVA-NP+M1) to activate M1-specific CD8+ T-cell response, including TRM cells, in nasopharynx-ass

191 MVA-NP+M1 elicits a substantial M1-specific T-cell response, including TRM cells, in nasopharynx-ass

192 Here, we have studied the early tonsillar T-cell responses induced in children after LAIV.

193 f the APC(s) involved in the priming of this T cell response is (are) poorly defined.

194 ction, a highly frequent class I allele, the T cell response is dominated by an epitope spanning resi

195 lass I molecules, the latent-specific CD8(+) T cell response is focused on epitopes derived from the

196 Induction of memory T cell response is inefficient in colorectal cancer (CRC

197 gulation of the MHC class II-mediated CD4(+) T cell response is understudied in endogenous MHC class

198 CD8 T cell responses likely play an important role in the co

199 esponsive host gene expression, HIV-specific T cell responses, low-level HIV viremia, rca-RNA, and th

200 antibody responses, suboptimal induction of T-cell responses may reduce protection.

201 Notably, we found that a poor T cell response negatively correlated with patients' age

202 t transient boost of the SIV-specific CD8(+) T cell responses occurred in IL-2-DT-treated RMs.

203 We aimed to compare the CD4+ and CD8+ T-cell responses of the high-dose (HD) and the standard-

204 and allows for robust endogenous CD8 and CD4 T cell responses on neoantigen induction in peripheral t

205 plasticity and shape both local and systemic T cell responses on reinfection.

206 ncreases in pathogen-specific functional CD4 T-cell responses on ART, and early decreases in lung fun

207 d participants had significantly higher CD8+ T-cell responses (P = .03).

208 T-cell responses peaked at day 14 after a single standar

209 In the ChAdOx1 nCoV-19 group, spike-specific T-cell responses peaked on day 14 (median 856 spot-formi

210 ptide pools in most individuals, with CD4(+) T cell responses predominating over CD8(+) T cell respon

211 f H-2D(b) on CD11c(+) APCs mitigates the CD8 T cell response, preventing early viral clearance and im

212 Glycopeptide-induced CD4(+) T cell response prior to Env trimer immunization elicits

213 s able to activate tumor neoantigen-specific T cell responses, providing a potent, individual tumor-s

214 he fourth vaccination) and Env-specific CD4+ T-cell response rates after the third and fourth vaccina

215 CD4+ T-cell response rates were higher at month 18 than month

216 CD4+ T-cell response rates were significantly higher with DNA

217 antiviral responses and SARS-CoV-2-specific T cell responses remained similar between the two groups

218 ntitumor immunity, but promoting durable CAR T cell responses remains challenging.

219 late and coordinate alphabeta and gammadelta T cell responses remains unknown.

220 by which the OX40 cosignaling regulates the T-cell response remains obscure.

221 (+)TNFalpha(+) and IFNgamma(+) IL2(+) CD4(+) T cell responses respectively, in comparison to 33% and

222 the CNS is cleared in C57BL/6 mice by a CD8 T cell response restricted by the MHC class I molecule H

223 Many epitope-specific CD8 T cell responses restricted by these four MHC molecules

224 ulture assay was also used to analyze memory T cell responses.RESULTSWe found responses to the spike

225 between them, polyfunctional gE-specific CD4 T-cell responses, safety, and confirmed HZ cases were as

226 pic model of TCR signaling in which multiple T cell responses share a common rate-limiting threshold

227 Current immunotherapies involving CD8+ T cell responses show remarkable promise, but their effi

228 B*57:01-restricted, HIV epitope-specific CD8 T-cell responses showed beneficial functional patterns a

229 teps are involved to elicit extensive memory T cell response: stimulation of naive T cells with robus

230 dly directed and functionally replete memory T cell responses, suggesting that natural exposure or in

231 lerance to livers, likely due to greater CD8 T cell responses than in the kidney model.

232 results in a CXCR5+ CCR7+ Tfh/central memory T cell response that persists well after parasite cleara

233 CSP has been shown to induce robust CD8(+) T cell responses that are capable of eliminating develop

234 ation, and functionality of RHV-specific CD8 T cell responses that are essential for protection again

235 The Matrix-M1 adjuvant induced CD4+ T-cell responses that were biased toward a Th1 phenotype

236 idence of complement activation and a robust T cell response, the patient developed persistent SARS-C

237 We set out to characterize the human CD4(+) T cell response throughout primary TBE immunization.

238 ctivation that primes a Tc1-polarized CD8(+) T cell response to bolster tumor rejection.

239 ovide the first glimpse of the overall human T cell response to HPV in a clinical setting and offer g

240 ive regulator of the early innate gammadelta T cell response to mucosal injury.

241 CD8+ T cell response to vaccination is impaired as a result o

242 tion also reported Notch signaling in CD8(+) T cell responses to dendritic cell immunization, Listeri

243 We likewise consider that potent, nonclonal T cell responses to microbial superantigens may reflect

244 ger a bystander effect leading to additional T cell responses to nonviral tumor-associated antigens t

245 rance prevents autoimmunity, but also limits T cell responses to potentially immunodominant tumor epi

246 ) T cells, and improved regulation of CD4(+) T cell responses to proinsulin at 9 months of age, as co

247 suppressing the activation of inappropriate T cell responses to resident microorganisms.

248 Overall, T cell responses to SARS-CoV-2 are robust; however, CD4(

249 studies have highlighted various aspects of T cell responses to SARS-CoV-2 infection that are starti

250 -gamma release assay (IGRA) for detection of T cell responses to SARS-CoV-2.

251 CD4(+) T cell responses to spike, the main target of most vacci

252 Ex vivo examination of cytotoxic T cell responses to the entire HIV-1 proteome from infec

253 then focused on HCoV-NL63 and detected broad T cell responses to the spike protein and identified 22

254 The T-cell response to chlamydia genital tract infections in

255 y infected with CL13 mounted a strong CD8(+) T-cell response to ECTV-Delta036 and survived without si

256 ctivated a marked interferon gamma-secreting T-cell response to M1 peptides.

257 t sequence diversity, the ability of the CD8 T-cell response to recognize several variants of a singl

258 As reviewed herein, the T-cell response to vaccination requires a fine balance b

259 T-cell responses to 50 frequently recognized Amb a-deriv

260 In this study, we analyze CD4 T-cell responses to influenza vaccination in subjects wh

261 type 1 diabetes is characterized by effector T-cell responses to pancreatic beta-cell-derived peptide

262 thers with T1D had reduced cord blood CD4(+) T-cell responses to proinsulin and insulin, a reduction

263 ared HLA-B*57:01-restricted HIV-specific CD8 T-cell responses to responses restricted by other HLA cl

264 nt to develop vaccines that can also mediate T-cell responses to SARS-CoV-2 to limit severity of infe

265 T-cell responses to severe acute respiratory syndrome co

266 Recently, we showed they can also rewire T-cell responses to soluble ligands.

267 ates of hospitalization and decreased memory T-cell responses to tetanus vaccine were associated with

268 ly defective ECTV-specific CD8(+) and CD4(+) T-cell responses to WT ECTV.

269 ings enhance our understanding of the CD8(+) T cell response toward a common EBV determinant in HLA-B

270 However, T cell response trajectory over the disease course remai

271 T-cells is hypothesized to trigger a CD8(+) T-cell response underpinning the hypersensitivity.

272 T cell responses upon infection display a remarkably rep

273 A vigorous anti-donor type T cell response was detected in vitro and conventional i

274 asis, the ability of VISTA to restrain naive T cell responses was lost under inflammatory conditions.

275 The proportion with islet-specific T cell responses was not significantly different over ti

276 However, the influenza-specific CD8+ T-cell response was lower in infected subjects than resp

277 Increased CD4(+) T cell responses were detected in eight individuals.

278 SARS-CoV-2-specific T cell responses were driven by TCR clusters shared betw

279 The increased T cell responses were due both to newly detectable react

280 ndent cohorts showed that alpha-syn-specific T cell responses were highest shortly after diagnosis of

281 e novo neoantigen-specific CD4(+) and CD8(+) T cell responses were observed post-vaccination in all o

282 breadth and overall strength of HPV-specific T cell responses were significantly higher before the co

283 The breadth and magnitude of T cell responses were significantly higher in severe as

284 In 3 patients, virus-specific T-cell responses were analyzed using T-cell enzyme-linke

285 Antibody and T-cell responses were assessed before upper- and lower-a

286 For 6 epitopes, CD8+ T-cell responses were confirmed in T cells derived from

287 Antibody and T-cell responses were higher in the 1.8 x 106 PfSPZ grou

288 Total memory T-cell responses were measured after anti-CD3 or vaccini

289 licited influenza-specific CD4(+) and CD8(+) T-cell responses were measured using flow cytometry and

290 Peptide-specific T-cell responses were tracked over time, and functional

291 L25 enhanced splenic and vaginal Ag-specific T cell responses whereas CCL28 increased the levels of s

292 ed a high titer of neutralizing Abs but poor T cell responses, whereas Aer induced powerful respirato

293 ight of 'protective' or 'detrimental' CD8(+) T cell responses which are restricted by the host HLA cl

294 Vaccine-induced CD8(+) T cell responses, which were predominantly directed agai

295 ive range, multifunctional CD8(+) and CD4(+) T cell responses with S protein-specific killing activit

296 e tested for their effect on the size of the T cell response, with a>=50% loss defined as an escape m

297 CD2 downregulation may attenuate antitumor T cell responses, with implications for checkpoint immun

298 ads to the development of a strong anti-ZIKV T-cell response without eliciting significant anti-ZIKV

299 A-B*52:01-restricted p24 Gag-specific CD8(+) T-cell response without incurring a significant loss to

300 magglutinin (HA) protein resulted in anti-HA T-cell responses without the development of significant